

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88804

Byeang Hyeon KIM, et al.

Appln. No.: 10/541,769

Group Art Unit: Unassigned

Confirmation No.: Unassigned

Examiner: Unassigned

Filed: July 8, 2005

For: NEW PHOSPHORAMIDITE COMPOUNDS

**SUBMISSION OF SEQUENCE LISTING AND
STATEMENT UNDER 37 C.F.R. §§ 1.821-1.825**

RECEIVED
JUL 10 2005

MAIL STOP SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As of January 10, 2006, no "Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)," for the above application, has been received.

Applicant respectfully submits herewith a substitute Sequence Listing and a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825 with respect to the above-referenced patent application. In addition, Applicant includes herewith a paper copy (5 pages) and computer readable form copy of the Sequencing Listing.


Applicants assert that this Submission of Sequence Listing and the enclosures are being timely filed, and that the enclosures bring the present application in full compliance with the requirements of 37 C.F.R. §§1.821-1.825.

KIM et al.
Appln. no. 10/541,769
Atty. Dkt.: Q88804

Applicants respectfully request that the Examiner acknowledge that the substitute Sequence Listing in the present application meets the requirements of 37 C.F.R. §§1.821-1.825 and that the Examiner enter the enclosed Sequence Listing.

A check for the statutory fee of \$65.00 (Small Entity) is attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Sunhee Lee
Registration No. 53,892

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: January 10, 2006

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88804

Byeang Hyeon KIM, et al.

Appln. No.: 10/541,769

Group Art Unit: Unassigned

Confirmation No.: Unassigned

Examiner: Unassigned

Filed: July 8, 2005

For: NEW PHOSPHORAMIDITE COMPOUNDS

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

MAIL STOP SEQUENCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In connection with the Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include any new matter;
2. the contents of the five (5)-page Sequence Listing being filed herewith, and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and
3. all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that